Literature DB >> 11081870

Malignant laryngotracheal obstruction: a way to treat serial stenoses of the upper airways.

K Wassermann1, F Mathen, H Edmund Eckel.   

Abstract

BACKGROUND: Six patients known to have inoperable esophageal carcinoma presented with stridor due to both malignant tracheal stenosis (n = 6) and bilateral vocal cord paralysis. Two patients also had respiratory-digestive fistula.
METHODS: Patency was restored by endotracheal stenting plus unilateral cordectomy. Four patients had immediate relief. Two patients required enlargement of the cord incision. One of them declined reoperation and underwent tracheotomy.
RESULTS: Stent function was uneventful. There was no dislodgement or mucous impaction. Fistula seal was complete. There was no aspiration through the new-shaped glottic orifice. Peak expiratory flow increased from 24.4% +/- 9.7% predicted normal before to 40.5% +/- 13.7% after the procedure, whereas the dyspnea score decreased from 74.2 +/- 12.7 to 24.2 +/- 14.0.
CONCLUSIONS: Restoration of airway continuity in serial laryngotracheal stenoses using a combined approach is a feasible technique in end-stage cancer patients. It effectively relieves respiratory distress and ensures voice preservation. In addition, it may avoid the risks of tracheotomy.

Entities:  

Mesh:

Year:  2000        PMID: 11081870     DOI: 10.1016/s0003-4975(00)01614-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

Review 1.  Thoracic oesophageal cancer as a cause of stridor: a literature review.

Authors:  Robert Munashe Maweni; Venughanan Manikavasagar; Nicholas Sunderland; Sajid Chaudhry
Journal:  BMJ Case Rep       Date:  2018-05-29

2.  Doxycycline-Eluting Core-Shell Type Nanofiber-Covered Trachea Stent for Inhibition of Cellular Metalloproteinase and Its Related Fibrotic Stenosis.

Authors:  Rengarajan Baskaran; Un-Jeong Ko; Enkhzaya Davaa; Ji Eun Park; Yixin Jiang; Junghan Lee; Su-Geun Yang
Journal:  Pharmaceutics       Date:  2019-08-19       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.